Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Procedures of automatic immunostaning for CD80, CD86 and PD-L1 in this study

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Polymer, Amplification, Blocking Assay

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Immunohistochemistry for CD80, CD86 and PD-L1 in NSCLC. A : CD80 was immunolocalized in tumor-infiltrating immune cells (IC) adjacent to tumor cells (TC). B : CD68 immunoreactivity in the same area as A. A great majority of CD80-positive cells is CD68-positive macrophages. C : Some CD80-positive cells (upper panel) were considered as CD3-positive T lymphocytes (lower panel) in this area. D : CD86 immunoreactivity was mainly detected in macrophages in IC. E : PD-L1 immunoreactivity was mainly detected in macrophages in IC. Same area as A. F : PD-L1 immunoreactivity was detected in TC, but not in IC, in this area. Bar = 50 μm, respectively.

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Immunohistochemistry

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between CD80 and clinicopathological parameters in 75 lung carcinomas

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between CD86 and clinicopathological parameters in 75 lung carcinomas

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Overall survival of 75 NSCLC patients according to CD80, CD86, PD-L1 (IC), PD-L1 (TC) and combined CD80/PD-L1 (IC) status. The solid line shows their high group, and the dashed line shows their low group in A–D. P -values < 0.05 were considered significant and shown in bold.

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Association between mRNA expression of CD80, CD86 and PD-L1 and overall survival in lung cancer patients using Kaplan-Meir Plotter for lung cancer. The mRNA expression level in each case was classified into two groups (high (red line) and low (black line)) by the median value (n = 1,925).

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques: Expressing

Journal: Acta Histochemica et Cytochemica

Article Title: Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor

doi: 10.1267/ahc.21-00075

Figure Lengend Snippet: Univariate and multivariate analyses of overall survival in 75 lung cancer patients

Article Snippet: Rabbit monoclonal antibodies for CD80 (ab269587, clone EPR1157(2)), CD86 (ab134120, clone EP1158-37) and PD-L1 (SP142) were purchased from Abcam (Cambridge, UK), Abcam and Roche Diagnostics Japan (Tokyo, Japan), respectively.

Techniques:

Journal: Frontiers in Oncology

Article Title: Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection

doi: 10.3389/fonc.2025.1649619

Figure Lengend Snippet: Immunohistochemical detection of CD163 + and CD86 + TAMs in colorectal tissues (×200). (A) CD163 staining in various tissues. (B) CD86 staining. (C) IOD for CD163. (D) IOD for CD86. Data expressed as M (Q1, Q3) (n = 109). * P < 0.05, ** P < 0.01, *** P < 0.001 (DB-adjusted). Groups: 1, Normal; 2, CAS; 3, SSA; 4, CRC. M: Median; Q 1 : 1st Quartile; Q 3 : 3rd Quartile.

Article Snippet: The following reagents and equipment were used in this study: mouse monoclonal anti-CD163 antibody (10D6, ma5-11458, Invitrogen, Waltham, MA02451, USA); rabbit monoclonal anti-CD86 antibody (EP1158-37, ab269587, Abcam, Cambridge, UK); rabbit Polyclonal a nti-CD68 antibody ( GB113150 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD163 antibody ( GB113152 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD86 antibody ( GB115630 , Servicebio, Wuhan, China); secondary antibodies and DAB chromogenic kits (Biomiky, Biosharp, and Servicebio, respectively).

Techniques: Immunohistochemical staining, Staining

Journal: Frontiers in Oncology

Article Title: Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection

doi: 10.3389/fonc.2025.1649619

Figure Lengend Snippet: Correlation of CD163 + /CD86 + TAMs levels with CRC development. (A) Differential expression between H.pylori -infected and uninfected groups. (B) Correlation between CD163 + and CD86 + expression. (C, D) Positive correlation of both markers with malignancy grade. Groups: 1, Normal; 2, CAS; 3, SSA; 4, CRC. *** P < 0.001 (MWU test).

Article Snippet: The following reagents and equipment were used in this study: mouse monoclonal anti-CD163 antibody (10D6, ma5-11458, Invitrogen, Waltham, MA02451, USA); rabbit monoclonal anti-CD86 antibody (EP1158-37, ab269587, Abcam, Cambridge, UK); rabbit Polyclonal a nti-CD68 antibody ( GB113150 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD163 antibody ( GB113152 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD86 antibody ( GB115630 , Servicebio, Wuhan, China); secondary antibodies and DAB chromogenic kits (Biomiky, Biosharp, and Servicebio, respectively).

Techniques: Quantitative Proteomics, Infection, Expressing

Journal: Frontiers in Oncology

Article Title: Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection

doi: 10.3389/fonc.2025.1649619

Figure Lengend Snippet: Multiplex immunofluorescence (200×) : CD68 + (red), CD163 + (green), CD86 + (green), DAPI (nuclei, blue), Merge (multichannel overlay), Scale bar: 50 μm. (A) CD68 + CD163 + dual-positive cells (IF). (B) CD68 + CD86 + dual-positive cells (IF).

Article Snippet: The following reagents and equipment were used in this study: mouse monoclonal anti-CD163 antibody (10D6, ma5-11458, Invitrogen, Waltham, MA02451, USA); rabbit monoclonal anti-CD86 antibody (EP1158-37, ab269587, Abcam, Cambridge, UK); rabbit Polyclonal a nti-CD68 antibody ( GB113150 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD163 antibody ( GB113152 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD86 antibody ( GB115630 , Servicebio, Wuhan, China); secondary antibodies and DAB chromogenic kits (Biomiky, Biosharp, and Servicebio, respectively).

Techniques: Multiplex Assay, Immunofluorescence

Journal: Frontiers in Oncology

Article Title: Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection

doi: 10.3389/fonc.2025.1649619

Figure Lengend Snippet: Changes in cell density and proportion of CD68 + CD163 +/ CD68 + CD86 + dual-positive TAMs across groups. Groups: 1, Normal; 2, CRA; 3, CRC. *** P < 0.001 (Tukey HSD).

Article Snippet: The following reagents and equipment were used in this study: mouse monoclonal anti-CD163 antibody (10D6, ma5-11458, Invitrogen, Waltham, MA02451, USA); rabbit monoclonal anti-CD86 antibody (EP1158-37, ab269587, Abcam, Cambridge, UK); rabbit Polyclonal a nti-CD68 antibody ( GB113150 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD163 antibody ( GB113152 , Servicebio, Wuhan, China); rabbit Polyclonal anti-CD86 antibody ( GB115630 , Servicebio, Wuhan, China); secondary antibodies and DAB chromogenic kits (Biomiky, Biosharp, and Servicebio, respectively).

Techniques:

Journal: Molecular Biomedicine

Article Title: Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion

doi: 10.1186/s43556-024-00203-0

Figure Lengend Snippet: Effect of FGF2 deficiency on BMDM apoptosis and polarization. a – c FGF2 deletion increased BMDM apoptosis. a Apoptosis in BMDM deprived of FBS for 24 h was assessed by flow cytometry ( n = 4). b - c Percentage of PI + Annexin V + and PI- Annexin V + BMDM after starvation. d - k FGF2 deletion in BMDM promoted M1 polarization. d - g Flow cytometric analysis of macrophage markers in BMDM treated with LPS or IL4, including CD86, iNOS, CD206, and Arg1 ( n = 3). h - k The levels of CD86, iNOS, CD206 and Arg1 in BMDM after treatment with LPS or IL4. N represents no treatment; * p < 0.05, vs. WT; Ψ p < 0.05, vs. N + WT; Ω p < 0.05, vs. N + FGF2 KO

Article Snippet: The tissue sections were incubated overnight at 4°C with primary antibodies, including the rabbit polyclonal antibody CD206 (1:200, Cat No. A02285-2, Boster, Wuhan, China), rabbit monoclonal antibody CD86 (1:100, Cat No. BM4121, Boster, Wuhan, China), rabbit polyclonal antibody F4/80 (1:100, Cat No. 29414-1-AP, Proteintech, Wuhan, China), anti-mouse NLRP3 (1:200, Cat No.68102-1-Ig, Proteintech, Wuhan, China), Caspase-1 p20 Rabbit pAb (1:400, Cat No.bs-10743R, Bioss, Beijing, China) and ASC/TMS1 Rabbit PolyAb (1:200, Cat No.10500-1-AP, Proteintech, Wuhan, China).

Techniques: Flow Cytometry

Journal: Molecular Biomedicine

Article Title: Deleting fibroblast growth factor 2 in macrophages aggravates septic acute lung injury by increasing M1 polarization and inflammatory cytokine secretion

doi: 10.1186/s43556-024-00203-0

Figure Lengend Snippet: Mice reconstituted with FGF2 KO macrophages and subjected to CLP demonstrate increased M1 polarization in lung tissue. a - f The presence and levels of CD206, CD86, and F4/80 markers on macrophages within lung tissue were identified and quantitatively assessed using immunofluorescence staining. Bar is 20 μm. * p < 0.05, vs. WT; Δ p < 0.05 vs. WT + LPS; # p < 0.05 vs. FGF2 KO

Article Snippet: The tissue sections were incubated overnight at 4°C with primary antibodies, including the rabbit polyclonal antibody CD206 (1:200, Cat No. A02285-2, Boster, Wuhan, China), rabbit monoclonal antibody CD86 (1:100, Cat No. BM4121, Boster, Wuhan, China), rabbit polyclonal antibody F4/80 (1:100, Cat No. 29414-1-AP, Proteintech, Wuhan, China), anti-mouse NLRP3 (1:200, Cat No.68102-1-Ig, Proteintech, Wuhan, China), Caspase-1 p20 Rabbit pAb (1:400, Cat No.bs-10743R, Bioss, Beijing, China) and ASC/TMS1 Rabbit PolyAb (1:200, Cat No.10500-1-AP, Proteintech, Wuhan, China).

Techniques: Immunofluorescence, Staining

Journal: Materials Today Bio

Article Title: In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

doi: 10.1016/j.mtbio.2022.100238

Figure Lengend Snippet: Dox/R837/PEGDA-PEGSH induced tumor immunogenic cell death and activated the immune system in vitro . (A) Western blotting analysis of HSP-70, HSP-90, CRT and PD-L1 expression in B16F10 cells after the different treatment for 24 h. (B-E) Relative protein expression levels of CRT (B), HSP-70 (C), HSP-90 (D) and PD-L1 (E) in B16F10 cells after different treatments analyzed from Western blotting were shown in each bar. (F-G) Extracellular levels of ATP (F) and HMGB1 (G) after different treatments were shown in each bar. (H) CD86 positive cells rates of dendritic cells after different treatments were shown in each bar. (I) Representative flow cytometry analysis of the maturation of dendritic cells which were co-cultured with the B16F10 cells after grouped treatment. Data are present as means ± SEM (n ≥ 3). Statistical significance: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001 vs the control group.

Article Snippet: Primary antibodies against LC3, Poly-ADP-ribose polymerase-1 (PARP-1), CD161c (NK1.1) were purchased from Cell Signaling Technology (Boston, Massachusetts, USA); N -cadherin, E-cadherin, Vimentin, P62, CRT, HSP-70, HSP-90, GPX-4, Ki67, PD-L1, Bax and β-actin were purchased from Proteintech (Wuhan, China); poly-ADP ribose (PAR) and Anti-cleaved N -terminal Gasdermin-D ( N -GSDMD) were purchased from Abcam (Cambridge, UK); CD8a was purchased from Thermo Fisher (Waltham, Massachusetts, USA); CD4, CD11c, F4/80, CD86 and CD206 were purchased from CUSABIO (Houston, USA).

Techniques: In Vitro, Western Blot, Expressing, Flow Cytometry, Cell Culture, Control

Journal: Materials Today Bio

Article Title: In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

doi: 10.1016/j.mtbio.2022.100238

Figure Lengend Snippet: Antitumor immune response induced by Dox/R837/PEGDA-PEGSH in spleen, blood and tumors. (A) The flow chart of the animal experiment. (B) The extracted splenocytes were co-cultured with melanoma cells at the proportion of 1:5, 1:10 and 1:20. Then the crystal violet experiment showed inhibitory effects of splenocytes on the growth of melanoma cells. (C) The schematic diagram of the co-culture between splenocytes and melanoma cells in different ratios. (D-F) CCK-8 assay proved the inhibitory effect of splenocytes on the cell viability of melanoma cells at the co-culture proportion of 1:5 (D), 1:10 (E) and 1:20 (F). (G) Cell flow cytometry analysis of the percentage of CD8 + cells in blood, spleens and tumors after different treatments. (H) Cell flow cytometry analysis of the percentage of IFN-γ+ cells in tumor CTLs after different treatments. (I) Cell flow cytometry analysis of the percentage of CD11c + CD45 + cells in spleens, blood and tumors after different treatments. (J) Cell flow cytometry analysis of the percentage of CD86 + cells in splenic dendritic cells, blood dendritic cells and dendritic cells in tumors after different treatments. Data are present as means ± SEM (n ≥ 3). Statistical significance: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001 vs the control group.

Article Snippet: Primary antibodies against LC3, Poly-ADP-ribose polymerase-1 (PARP-1), CD161c (NK1.1) were purchased from Cell Signaling Technology (Boston, Massachusetts, USA); N -cadherin, E-cadherin, Vimentin, P62, CRT, HSP-70, HSP-90, GPX-4, Ki67, PD-L1, Bax and β-actin were purchased from Proteintech (Wuhan, China); poly-ADP ribose (PAR) and Anti-cleaved N -terminal Gasdermin-D ( N -GSDMD) were purchased from Abcam (Cambridge, UK); CD8a was purchased from Thermo Fisher (Waltham, Massachusetts, USA); CD4, CD11c, F4/80, CD86 and CD206 were purchased from CUSABIO (Houston, USA).

Techniques: Cell Culture, Co-Culture Assay, CCK-8 Assay, Flow Cytometry, Control

Journal: Materials Today Bio

Article Title: In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

doi: 10.1016/j.mtbio.2022.100238

Figure Lengend Snippet: Immune cells infiltration and immunogenic cell death activation in the primary tumor sites. (A) IHC staining analyzed of CD8a (marker for CTLs), CD4 (marker for helper T cells), CD11c (marker for dendritic cells), CD161c (marker for NK cells), F4/80 (marker for macrophages), CD86 (marker for M1 macrophages) and CD206 (marker for M2 macrophages) from paraffin-embedded sections of the tumor tissues. Scale bar = 200 μm. (B) Western blotting analysis of HSP-70, HSP-90, CRT and PD-L1 expression in tumor tissues after the different treatment in vivo . (C–F) The protein levels of HSP-70 (C), HSP-90 (D), PD-L1 (E) and CRT (F) of the tumor tissues after different treatments were shown in each bar. (G-M) CD8a (G), CD4 (H), F4/80 (I), CD86 (J), CD206 (K), CD11c (L) and CD161c (M) positive cells rates of the tumor tissues after different treatments were shown in each bar. Data are present as means ± SEM (n ≥ 3). Statistical significance: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001 vs the control group.

Article Snippet: Primary antibodies against LC3, Poly-ADP-ribose polymerase-1 (PARP-1), CD161c (NK1.1) were purchased from Cell Signaling Technology (Boston, Massachusetts, USA); N -cadherin, E-cadherin, Vimentin, P62, CRT, HSP-70, HSP-90, GPX-4, Ki67, PD-L1, Bax and β-actin were purchased from Proteintech (Wuhan, China); poly-ADP ribose (PAR) and Anti-cleaved N -terminal Gasdermin-D ( N -GSDMD) were purchased from Abcam (Cambridge, UK); CD8a was purchased from Thermo Fisher (Waltham, Massachusetts, USA); CD4, CD11c, F4/80, CD86 and CD206 were purchased from CUSABIO (Houston, USA).

Techniques: Activation Assay, Immunohistochemistry, Marker, Western Blot, Expressing, In Vivo, Control